Pre-Launch Promotional Planning Under FDA Preapproval Publicity Rules

The controlling rule is concise enough to set out here. Section 312.7(a) of title 21 bars sponsors from selling a still-investigational drug on safety or efficacy grounds for the uses under study, or promoting it otherwise, before FDA action. Everything turns on whether the communication is promotional. Because the drug is still being studied, FDA lacks a complete record on its safety and effectiveness, so commercial promotion during that period creates impressions the agency cannot confirm or deny. When a sponsor tells a doctor, patient, or investor the unapproved product works, it is asserting something FDA has not approved.

The sponsor is not being silenced by any of this. The regulation explicitly permits complete scientific dialogue regarding the drug, so findings remain shareable through professional meetings, publications, and conversations with doctors. The rule forbids framing that exchange in a promotional light, or advancing product claims ahead of any approval. The consequences reach beyond this rule. The FDCA can treat a preapproval-promoted product shipped across state lines as adulterated or misbranded, with liability attaching even when the promotional claim has no physical connection to the product itself, whether it surfaces online or at a distant conference booth. Products under an IND carry a mandatory disclosure: each must display the words "Caution: New Drug, Limited by Federal (or United States) law to investigational use," with sponsors responsible for ensuring that this warning accompanies the product wherever it appears.

How OPDP enforces the rule

FDA's Office of Prescription Drug Promotion (OPDP) is responsible for seeing that advertising and promotion of prescription drugs stay accurate, balanced, and free of misleading claims. Its work runs along three tracks: advising sponsors in writing on promotional pieces sent in ahead of use, examining complaints that allege violations, and issuing either an untitled or a warning letter once a violation turns up. The two letter types differ in severity. An untitled letter flags a violation without pursuing it criminally, while a warning letter carries greater legal weight and demands stronger correction. The equivalent job for licensed biologics falls to FDA's Advertising and Promotional Labeling Branch. So a compliance team covering drugs as well as biologics must follow two separate offices.

OPDP is not confined to reviewing paperwork that comes in from headquarters. In the Alar matter, agency personnel turned up in person at professional congresses, moved through exhibit halls, collected booth materials, and took photos of displays without first alerting the sponsor. When monitors arrive without notice and assess promotion on site, a major-conference booth can be reviewed as closely as a print ad filed with the agency, and sometimes more. Sponsors can also be vulnerable outside OPDP: both civil and criminal state consumer protection regimes target deceptive advertising, while competitors claiming commercial injury may bring Lanham Act suits over allegedly false or misleading statements. That final risk can reach investigational-product sponsors no less easily than drug makers with approved products.

What the Alar Pharmaceuticals enforcement action reveals about where the line sits

FDA's August 21, 2026 Untitled Letter directed at Alar Pharmaceuticals matters far beyond the company itself. OPDP's initial enforcement letter on this subject came after the February 2022 Warning Letter reached CytoDyn, while also marking the agency's first Untitled Letter addressing this area since Nascent Biotech received one in November 2019. Since such enforcement actions can be years apart, each one offers a valuable glimpse into the agency's current focus.

FDA identified ALA-3000 injection, a long-acting ketamine candidate being studied for TRD, as the item exhibited during the American Psychiatric Association's 2026 Annual Meeting. The exhibit booth and its handout asserted sweeping safety and efficacy conclusions, declaring the candidate "Breaks Key Barriers in Ketamine Therapy for TRD" and carries "No overall sedative, dissociative, psychosis-like side effects." OPDP objected that such claims drew support only from Phase 1 data, calling the mismatch "extremely concerning" in light of the early stage of clinical development. The materials also implied comparisons casting the candidate as superior to or more favorable than approved TRD therapies already available, an implication made graver by ketamine's established risks and its Schedule III controlled substance classification. On top of that, the booth lacked any notice that the product was still in clinical testing and not yet cleared for commercial sale, so visitors saw no sign that anything shown there remained unapproved. Even where the booth stood mattered: positioned on the exhibit floor among displays for approved products, it projected a commercial impression before any attendee read a single claim.

This did not come to FDA's attention via online surveillance or social media tracking. An OPDP representative examined the physical display and printed materials on site, producing records that feature the handout alongside an image of the exhibit where faces are obscured yet name tags and signage remain clear. Alar does not teach that one isolated assertion went too far. By merging Phase 1 results, sweeping safety claims, comparisons with authorized treatments, the absence of any investigational-status notice, and a booth beside approved-product neighbors, the overall promotional setting prevented OPDP from treating it as scientific exchange. Individually, these factors might have prompted less scrutiny, but collectively they formed a compelling enforcement basis.

The communications that remain expressly permitted before approval

Everything a sponsor is still permitted to do before approval flows from the carve-out for scientific exchange in § 312.7(a), because nothing in the rule is meant to curb the open sharing of findings, including those that reach the public in scientific or lay-media outlets. Whether a particular communication lands inside that protection or falls outside it turns on what it says and the circumstances in which it appears, not on the topic it addresses. Investor communications remain on the table, though they continue to be bounded by the same securities-law principles that dictate how a public company may discuss its pipeline. Sponsors may also discuss their wider research programs and the underlying technologies, so long as the conversation doesn't slide into promoting a particular investigational product. General education about a disease is also allowed so long as it does not steer audiences toward one specific experimental therapy for that condition. Sponsors may still use advisory meetings and focus groups, with the same limits governing their conduct and participation. Recruiting investigators for clinical studies and enrolling research subjects also remains a permitted category of its own, apart from commercial promotion.

Medical affairs functions take up a central place on this map. Medical science liaisons walk opinion leaders through the underlying biology of a product still under study during the initial pre-launch phase, covering trial progress, anticipated milestones, and findings as soon as they surface, provided the exchange respects the rule against pre-approval product promotion, weighs upside and downside evidence evenly, and is framed as scientific dialogue. Drawing on disease-background and mechanism-of-action slide decks, medical-meeting and congress data summaries, and the latest clinical practice guideline updates, MSLs carry out this work. The real test is whether the content actually advances scientific knowledge or is quietly steering toward a sales pitch.

A separate, more limited set of principles governs firm discussions of off-label uses for products with approval, not promotion of an investigational product with no approved indication. FDA released on January 7, 2025, its final "Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products, Questions and Answers," the document often referred to as SIUU Final Guidance. The guidance offers firms a limited safe harbor: if their communications follow its recommendations, FDA will not rely on those statements alone to establish that the product has a new intended use. Sponsors should treat this guidance as separate from the wider investigational-promotion framework discussed above; it addresses communications about products already on the market, rather than statements about a drug before its first approval.

Pre-approval payer engagement under the 2026 draft guidance

Payer engagement occupies its own place among the categories above, since a stand-alone law provides its authorization. One such measure, Pre-Approval Information Exchange Act by name, lets drug makers convey data on science and health economics to health plans, formulary bodies, and similar decision-makers ahead of FDA action; it was passed via Section 3630 in the 2023 Consolidated Appropriations Act.

The framework now governing this work is FDA's June 2026 draft guidance, "Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities, Questions and Answers." The draft addresses three kinds of communication: health economic information on products already approved or cleared, information on drugs or devices still awaiting approval or clearance, and information on unapproved uses of products that are already approved. Because the June 2026 guidance remains a draft, any company building its compliance approach on top of it should treat the document as a structure that may still shift rather than fixed policy, monitoring open feedback and any revisions before committing payer engagement plans to today's wording. The reason for talking with payers early comes down to basic business sense: building the evidence, locking in formulary placement, and getting payer decision-makers on board all take time, and the industry has moved toward starting those conversations well over a year before an expected approval instead of waiting for the months right before launch.

The escalating enforcement environment for pre-launch communications

HHS and FDA changed the enforcement backdrop abruptly on September 9, 2025, launching a broad direct-to-consumer ad push with about 100 cease and desist notices. Most notices focused on compounded GLP-1 offerings and web-based marketing, rather than approved prescription-drug advertising, underscoring an effort unmatched in recent years: FDA sent only three DTC warning or untitled letters during 2023. The enforcement wave that came next identified specific companies and specific problems. OPDP criticized Novo Nordisk’s television spot for the Wegovy tablet, saying viewers could take away that the pill was more effective and safer than other approved GLP-1 treatments, plus unproven quality-of-life benefits. OPDP also faulted Alnylam Pharmaceuticals over consumer-facing Amvuttra webpages, saying they falsely or misleadingly characterized mortality effects among ATTR-CM patients. Together, the actions show how OPDP now tests concrete, verifiable clinical-benefit claims, including Alar’s booth statements about efficacy.

The rulemaking track points the same way. The agency's 2026 Unified Agenda now includes proposed rule RIN 0910-AJ14. The proposal would bar "adequate provision" for television and radio DTC prescription drug ads, instead requiring the full brief summary of risks, a mandate FDA and HHS acknowledge would make those spots too lengthy and costly to produce. The agency expects to issue the NPRM in December 2026. These rulemaking moves do not directly reach investigational product promotion, but they point to an agency applying closer review throughout the promotional space it regulates. That the Alar Untitled Letter surfaced amid this wider enforcement push is no coincidence. When the office ramps up its broader policing, marginal pre-launch messages face greater scrutiny, including within promotional areas where warning notices were previously uncommon. Treating the scarcity of past preapproval notices as evidence of safety means misinterpreting the data. That scarcity reflected OPDP's selective enforcement habits rather than any genuine flexibility built into the regulation.

The CRL transparency initiative and its effect on pre-launch communication planning

FDA's transparency initiative began in July 2025, publishing complete response letters just for drugs already holding approval. In September 2025, the agency widened this to cover complete response letters for drugs still awaiting approval, releasing them as they were issued. This is a clear change from past practice, when the agency made CRLs public only if a product later gained approval, which might never happen. Before, a sponsor getting a CRL decided when and how to share that news publicly. Today, that same unfavorable regulatory information can be released before the sponsor has chosen how, or even if, to describe it.

FDA's 2026 Unified Agenda lists one more proposed rule, slated for October 2026, letting the FDA Commissioner "clarify and expand" his discretion to make not-approvable letters and CRLs public. The agency says the rule will end the longstanding presumption that a marketing application is by itself confidential commercial information, though proprietary secrets and private personal details can still be blacked out. For sponsors drafting plans to communicate ahead of a launch, pairing immediate CRL releases with broader authority to disclose strips away a control layer that once applied automatically. A communication plan premised on keeping bad regulatory news under wraps until the sponsor decides to speak up is out of step with today's FDA, and launch preparation must now anticipate a CRL appearing publicly on the agency's schedule.